What is HC Wainwright’s Estimate for OmniAb FY2025 Earnings?

OmniAb, Inc. (NASDAQ:OABI) – Investment analysts at HC Wainwright boosted their FY2025 earnings per share (EPS) estimates for OmniAb in a note issued to investors on Wednesday, November 5th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of ($0.50) per share for the year, up from their previous estimate of ($0.59). The consensus estimate for OmniAb’s current full-year earnings is ($0.61) per share. HC Wainwright also issued estimates for OmniAb’s Q4 2025 earnings at ($0.06) EPS, FY2026 earnings at ($0.39) EPS, FY2027 earnings at ($0.32) EPS, FY2028 earnings at ($0.18) EPS and FY2029 earnings at ($0.16) EPS.

OmniAb (NASDAQ:OABI) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.01. The firm had revenue of $2.24 million during the quarter, compared to the consensus estimate of $5.64 million. OmniAb had a negative return on equity of 23.14% and a negative net margin of 301.83%. OmniAb has set its FY 2025 guidance at EPS.

Several other brokerages also recently weighed in on OABI. Weiss Ratings reissued a “sell (e+)” rating on shares of OmniAb in a research report on Tuesday, October 14th. Royal Bank Of Canada cut their target price on OmniAb from $4.00 to $3.00 and set an “outperform” rating on the stock in a research note on Thursday, August 7th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $6.67.

OmniAb Stock Performance

Shares of OABI stock opened at $1.38 on Friday. The company has a market capitalization of $198.66 million, a price-to-earnings ratio of -2.38 and a beta of 0.15. OmniAb has a one year low of $1.22 and a one year high of $4.63. The company’s 50-day moving average is $1.60 and its 200 day moving average is $1.70.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. AQR Capital Management LLC purchased a new stake in shares of OmniAb during the 1st quarter valued at about $25,000. Cerity Partners LLC purchased a new position in shares of OmniAb in the first quarter worth approximately $26,000. Osaic Holdings Inc. grew its position in OmniAb by 214.4% during the second quarter. Osaic Holdings Inc. now owns 14,247 shares of the company’s stock valued at $25,000 after buying an additional 9,716 shares during the period. PNC Financial Services Group Inc. increased its holdings in OmniAb by 279.4% during the first quarter. PNC Financial Services Group Inc. now owns 16,276 shares of the company’s stock valued at $39,000 after buying an additional 11,986 shares during the last quarter. Finally, Corient Private Wealth LLC purchased a new stake in OmniAb during the second quarter valued at approximately $53,000. Institutional investors own 72.08% of the company’s stock.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.